Altimmune, Inc. (NASDAQ:ALT) Expected to Post Quarterly Sales of $2.06 Million

Equities analysts expect Altimmune, Inc. (NASDAQ:ALTGet Rating) to post $2.06 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Altimmune’s earnings, with the highest sales estimate coming in at $5.00 million and the lowest estimate coming in at $200,000.00. Altimmune posted sales of $840,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 145.2%. The business is expected to report its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Altimmune will report full-year sales of $8.06 million for the current year, with estimates ranging from $800,000.00 to $20.00 million. For the next fiscal year, analysts forecast that the company will report sales of $20.00 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Altimmune.

Altimmune (NASDAQ:ALTGet Rating) last posted its quarterly earnings data on Tuesday, March 15th. The company reported ($0.57) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.64) by $0.07. Altimmune had a negative net margin of 2,200.61% and a negative return on equity of 38.26%. During the same quarter in the previous year, the business earned ($0.17) EPS.

Several research firms have recently issued reports on ALT. Jefferies Financial Group started coverage on shares of Altimmune in a report on Thursday, December 30th. They set a “buy” rating and a $30.00 price objective on the stock. B. Riley decreased their price objective on Altimmune from $27.00 to $21.00 in a report on Monday, January 24th. Guggenheim cut their target price on Altimmune from $33.00 to $28.00 in a research note on Wednesday, March 16th. Zacks Investment Research raised Altimmune from a “sell” rating to a “hold” rating in a research report on Wednesday, March 16th. Finally, HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of Altimmune in a report on Tuesday, March 22nd. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from, the company has a consensus rating of “Buy” and a consensus price target of $25.28.

Shares of Altimmune stock opened at $4.54 on Friday. The company has a market capitalization of $196.23 million, a PE ratio of -1.92 and a beta of 1.36. The company has a 50-day simple moving average of $6.51 and a two-hundred day simple moving average of $8.54. Altimmune has a one year low of $4.43 and a one year high of $19.46.

In other Altimmune news, insider Matthew Scott Harris sold 30,000 shares of Altimmune stock in a transaction that occurred on Monday, February 28th. The stock was sold at an average price of $7.52, for a total transaction of $225,600.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 3.14% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. Royal Bank of Canada raised its position in shares of Altimmune by 2,032.1% during the second quarter. Royal Bank of Canada now owns 3,987 shares of the company’s stock worth $39,000 after purchasing an additional 3,800 shares during the period. Morgan Stanley lifted its position in shares of Altimmune by 900.2% during the 2nd quarter. Morgan Stanley now owns 775,528 shares of the company’s stock worth $7,640,000 after purchasing an additional 697,988 shares during the last quarter. WINTON GROUP Ltd acquired a new position in shares of Altimmune during the 3rd quarter worth about $178,000. SG Americas Securities LLC acquired a new position in shares of Altimmune during the 3rd quarter worth about $305,000. Finally, Deutsche Bank AG raised its holdings in Altimmune by 18.2% in the 3rd quarter. Deutsche Bank AG now owns 22,802 shares of the company’s stock valued at $258,000 after acquiring an additional 3,508 shares in the last quarter. 82.36% of the stock is currently owned by hedge funds and other institutional investors.

About Altimmune (Get Rating)

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis.

Read More

Get a free copy of the Zacks research report on Altimmune (ALT)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Altimmune (NASDAQ:ALT)

Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with's FREE daily email newsletter.